We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+9.06%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$14.6B
AUM Growth
+$2.6B
(+22%)
Cap. Flow
+$859M
Cap. Flow
% of AUM
5.88%
Top 10 Holdings %
Top 10 Hldgs %
21.92%
Holding
958
New
131
Increased
364
Reduced
334
Closed
74
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$135M |
| 2 |
Royal Bank of Canada
RY
|
+$120M |
| 3 |
Agilent Technologies
A
|
+$72.5M |
| 4 |
UnitedHealth
UNH
|
+$71.5M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
+$64.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$90.3M |
| 2 |
Amgen
AMGN
|
+$88.7M |
| 3 |
Allstate
ALL
|
+$52.2M |
| 4 |
Union Pacific
UNP
|
+$47.1M |
| 5 |
Bio-Rad Laboratories Class A
BIO
|
+$44.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 33.42% |
| 2 | Technology | 23.2% |
| 3 | Consumer Discretionary | 9.14% |
| 4 | Financials | 8.63% |
| 5 | Communication Services | 7.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
Huntington Bancshares
HBAN
$34.7B
| $10.6M | 0.07% |
741,771
+474,940
| +178% | +$7.27M |
|
277
RadNet
RDNT
$4.84B
| $10.4M | 0.07% |
+309,211
| New | +$8.14M |
|
278
Cytokinetics
CYTK
$10.9B
| $10.2M | 0.07% |
513,344
+137,491
| +37% | +$3.23M |
|
|
IGMS
279
DELISTED
IGM Biosciences
IGMS
| $10.2M | 0.07% |
122,029
+13,137
| +12% | +$973K |
|
280
Zoetis
ZTS
$32.2B
| $10M | 0.07% |
53,816
+18,437
| +52% | +$3.2M |
|
281
American Tower
AMT
$77.7B
| $10M | 0.07% |
37,018
-37,858
| -51% | -$9.65M |
|
282
Blackrock
BLK
$165B
| $9.98M | 0.07% |
11,403
-7,407
| -39% | -$6.26M |
|
283
Beam Therapeutics
BEAM
$2.58B
| $9.93M | 0.07% |
+77,147
| New | +$6.15M |
|
284
Dollar General
DG
$27.2B
| $9.84M | 0.07% |
45,475
-19,687
| -30% | -$4.14M |
|
285
Pacific Biosciences
PACB
$422M
| $9.81M | 0.07% |
+280,431
| New | +$8.16M |
|
286
Olema Pharmaceuticals
OLMA
$1.05B
| $9.78M | 0.07% |
349,572
+349,559
| +2,688,915% | +$9.95M |
|
287
Twist Bioscience
TWST
$5.39B
| $9.71M | 0.07% |
+72,841
| New | +$8.47M |
|
288
Rigel Pharmaceuticals
RIGL
$692M
| $9.64M | 0.07% |
+222,170
| New | +$8.39M |
|
|
CNST
289
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $9.46M | 0.06% |
280,008
-131,507
| -32% | -$3.35M |
|
|
ORBC
290
DELISTED
ORBCOMM, Inc.
ORBC
| $9.46M | 0.06% |
+841,269
| New | +$9.33M |
|
291
GE Aerospace
GE
$375B
| $9.32M | 0.06% |
138,909
-11,011
| -7% | -$735K |
|
292
Quest Diagnostics
DGX
$25.6B
| $9.3M | 0.06% |
70,495
+14,485
| +26% | +$1.9M |
|
293
Mondelez International
MDLZ
$77.9B
| $9.3M | 0.06% |
148,972
-228
| -0.2% | -$14K |
|
|
ZGNX
294
DELISTED
Zogenix, Inc.
ZGNX
| $9.28M | 0.06% |
536,758
-327,768
| -38% | -$6.03M |
|
|
YMAB
295
DELISTED
Y-mAbs Therapeutics
YMAB
| $9.26M | 0.06% |
178,181
-1,764
| -1% | -$56.6K |
|
296
ManpowerGroup
MAN
$2.5B
| $9.24M | 0.06% |
+77,722
| New | +$9.17M |
|
297
Toronto Dominion Bank
TD
$198B
| $9.13M | 0.06% |
130,125
-12,788
| -9% | -$895K |
|
298
Intercontinental Exchange
ICE
$84.1B
| $9.12M | 0.06% |
76,862
+39,563
| +106% | +$4.55M |
|
299
Diageo
DEO
$47.3B
| $9.06M | 0.06% |
18,046
+18,038
| +225,475% | +$3.36M |
|
300
BioMarin Pharmaceuticals
BMRN
$11.6B
| $9M | 0.06% |
107,843
-250,187
| -70% | -$19.8M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2021 Portfolio in Review
As of Q2 2021, Candriam SCA held 958 positions worth $14.6B, up 22% from $12B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Candriam SCA deployed $859M of net new capital in Q2 2021, opening 131 new positions and adding to 364 existing holdings. Its largest new stake was SailPoint Technologies Holdings, Inc. Common Stock: 738,233 shares worth $37.7M.
By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 34% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $90.3M trimmed.
- Candriam SCA's largest Q2 2021 buy was SailPoint Technologies Holdings, Inc. Common Stock: 738,233 shares worth $37.7M.
- Candriam SCA added most to Microsoft in Q2 2021, an estimated $135M increase.
- Candriam SCA's biggest Q2 2021 reduction was Bristol-Myers Squibb, cutting an estimated $90.3M.
- Candriam SCA fully exited Tenable Holdings in Q2 2021, selling an estimated $31.6M.
- Candriam SCA's ten largest holdings make up 22% of its $14.6B portfolio in Q2 2021.
- Candriam SCA opened 131 new positions and closed 74 in Q2 2021.
- Candriam SCA's portfolio value rose 22% quarter-over-quarter to $14.6B.
Based on Candriam SCA's 13F filing for Q2 2021, filed 20 Jul 2021.